Guí a OncoSur de Cáncer de ovar io 86 > – Di Silvestro P, Banerjee S, Colombo N, Scambia N, Kim B, Oaknin A, et al. Overall survival at 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation who received maintenance olaparib in the SOLO1/GOG-3004 trial. Ann Oncol. 2022;33(Suppl 7):S235-82. DOI: 10.1016/annonc/ annonc1054 – Ray-Coquard I, Leary A, Pignata S, Cropet C, González Martín AJ, Bogner G, et al. Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer. Ann Oncol. 2022;33(Suppl 7):S808-69. DOI: 10.1016/ annonc/annonc1089 – Redondo A, Guerra E, Manso L, Martín-Lorente C, Martínez-García J, Pérez-Fidalgo JA, et al. SEOM Clinical Guideline in Ovarian Cancer, 2020. Clin Transl Oncol. 2021;23(5):961-8. E-pub: 30 de enero de 2021. DOI: 10.1007/s12094-020-02545-x. PMID: 33515422; PMCID: PMC8058000
RkJQdWJsaXNoZXIy MTQzMjMwMg==